Halozyme Therapeutics Inc. Earnings Growth Sends Shares Higher
By: Lucas Downey | Published: Oct 21, 2026
Overview
Halozyme Therapeutics Inc. (HALO) has seen a remarkable increase in its stock price, rising 910% since March 2014. The company specializes in developing innovative oncology treatments and a platform for subcutaneous drug delivery.
Recent Earnings Report
In its second-quarter fiscal 2026 earnings report, Halozyme reported:
- Revenue: $481 million (a record 48% year-over-year increase)
- Non-GAAP diluted earnings per share: $1.90 (a 42.9% increase)
The company has also raised its guidance for total revenue, royalty revenue, adjusted EBITDA, and EPS for 2026, indicating strong future prospects.
Stock Performance
HALO shares have surged 85% year-to-date, driven by significant institutional investment. MoneyFlows data indicates that large investors are heavily betting on the stock, as evidenced by unusual trading volumes.
Technical analysis from the previous trading sessions shows support at $121.59, a pivot point at $122.59, and resistance at $123.50.
Institutional Support
Halozyme has experienced strong institutional demand, with 32 outlier inflow signals since 2014, contributing to its impressive 910% growth since the first major investment by large investors. The stock has a solid fundamental backdrop, with:
- 3-year sales growth rate: +28.5%
- 3-year EPS growth rate: +28%
EPS is projected to increase by 20.8% this year, further attracting investor interest.
Future Outlook
Given the historical performance and strong fundamentals, Halozyme is positioned as a potential candidate for inclusion in diversified investment portfolios. The upcoming earnings report on November 9 is highly anticipated by investors.